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The Congress took place at the northernmost academic
center in the world, in the state-of-the art Tromso University
Hospital. There were over 500 participants, mainly from
Scandinavian countries, with approximately 50 invited par-
ticipants from non-Scandinavian countries, primarily from
Europe and the USA. The meeting was managed and orga-
nized by a local committee, chaired by the University of
Tromso Professor of Anaesthesiology Dr Lars Bjertneas.
Approximately 300 oral and poster presentations high-
lighted the latest progress in diverse areas of anaesthesiol-
ogy and intensive care medicine from Scandinavia. Invited
speakers held state-of-the art lectures in selected areas of
pathophysiology and therapy. The meeting benefited from
the support of various industry sponsors, and the abstracts
of the meeting were published in a supplement of Acta
Anesthesiologica Scandinavica.
Sepsis: the PROWESS study
Sepsis represents a major cause of mortality, affecting
750,000 patients/year in the USA, with 2000 new cases
identified each day and 700 deaths per year (2001 US
statistics). Much interest focused on the haemostatic
aspects of sepsis and septic shock. This interest stems
partly from the recent results of a multicenter trial that
demonstrated the beneficial effects and a significant sur-
vival benefit provided by APC infusion in septic patients.
Dr P Laterre (University Clinic, St Luc, Belgium) provided
a detailed overview of the recently completed clinical trial
with APC (or Drotecogin alpha; 24 mg/kg per h for 4 days
by intravenous infusion). In the PROWESS (Protein C
Worldwide Evaluation in Severe Sepsis) study, a 1690-
patient randomized trial that utilized inclusion criteria
similar to those of the preceding anticytokine trials, the
mortality rate in the placebo group was 30.8%, which
decreased to 24.9% in the treatment group. This corre-
sponds to a 6% reduction in mortality, which means that
for every 16 patients treated with APC one can expect to
save an additional life. 
That trial demonstrated no subgroup differences in
outcome, except for the very mild shock group (Acute
Physiology and Chronic Health Evaluation II score <19), in
which the drug tended to worsen the outcome. No sex,
race or age differences were noted in the efficacy of the
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Abstract
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine took
place in the state-of-the art Tromso University Hospital. There were over 500 participants, and
approximately 300 oral and poster presentations highlighted the latest progress in diverse areas.
Much interest focused on activated protein C (APC) and other ways forward in sepsis treatment, pain
management, novel markers of neurotrauma and antioxidants in bypass surgery. The meeting
continues to be the leading anaesthesiology and intensive care conference in the region.
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drug. Both the patients who presented with low pretrial
APC levels and the patients with normal APC levels bene-
fited, indicating that there is no need for measurements of
APC before instituting therapy. Pneumonia and lung infec-
tion were common causes of death, because of the fact
that during the trial two major influenza epidemics were
prevalent throughout the study centers. APC treatment
induced a faster decline in plasma IL-6 levels, indicating a
possible anti-inflammatory effect of the treatment.
In the APC arm, duration of intensive care unit stay was
slightly but significantly reduced, and there was a
reduction in catechol requirements and number of days
on a ventilator. The trial did not exclude any patients
except those with a tendency for higher bleeding com-
plications and severely moribund patients who were
expected to die within 24 h. The only noted side effect
was related to serious bleeding, of which the incidence
increased from 2 to 3.5% (P = 0.06). However, after
stopping the APC infusion, the effect of the drug quickly
diminished, and no mortality due to bleeding was noted.
After many unsuccessful trials, it appears that the first
‘magic bullet’ has arrived.
Other ways forward in sepsis
Nevertheless, if we are to improve survival further in
sepsis, then there is no doubt that additional therapies are
needed, as overviewed by Dr Else Tonnesen (Department
of Anesthesiology, Aarhus, Denmark). Potential ways to
affect the complement system in the future include the
complement regulator C1 inhibitor, the soluble comple-
ment receptor 1 and antibodies that neutralize C5, as
overviewed by Dr Tom Mollnes (Department of Immunol-
ogy, Nortland Center Hospital, Bodo, Norway). Dr Daniel
Traber (Department of Anesthesiology, University of Texas,
USA) demonstrated beneficial effects with recombinant
antithrombin III in a sepsis/smoke inhalation induced
model of severe systemic inflammatory response syn-
drome in sheep,
Although the Glaxo-Wellcome trial with the nitric oxide
(NO) synthase inhibitor NG-monomethyl-L-arginine was
discontinued some years ago because of lack of survival
efficacy, much interest still focuses on the role of NO
and related species in the pathogenesis of sepsis. Dr M
Kirov (State University Arhangelsk, Russia) and Lars
Bjertnaes (University of Tromso, Norway) presented clini-
cal data with methylene blue, a guanylate cyclase
inhibitor that presumably acts via blocking NO-induced
increases in cGMP levels in the vasculature of septic
patients. Administration of methylene blue in 20 patients
induced an increase in MAP, and a stabilization of stroke
volume and left ventricular stroke index. It reduced the
requirement for catecholamines, but did not improve
oxygen delivery and did not affect serum chemistry para-
meters of organ injury.
Dr Salvador Moncada (Wolfson Institute, London, UK)
presented novel data on the differential time-dependent
and dose-dependent regulation of mitochondrial respira-
tion and cell death by NO. Dr Csaba Szabo (Inotek Cor-
poration, Boston, MA, USA) presented evidence for the
pathogenetic role of peroxynitrite, a toxic reaction
product of NO, and the protective effect of peroxynitrite
decomposition catalysts in various rodent models of
shock. Dr Daniel Traber (University of Texas, USA) pre-
sented data with the inducible NO synthase inhibitor
mercaptoethylguanidine and with the NO scavenging
compound pyridoxalated haemoglobin polyoxyethylene in
various ovine models of sepsis. Dr Mikael Bodelsson and
colleagues (University Hospital Lund, Sweden) pre-
sented evidence that the endotoxin-binding antibiotic
bactericidal/permeability increasing protein is able to
attenuate the expression of inducible NO synthase in
septic blood vessels.
In addition to inhibition of NO and its toxic byproducts,
additional interest has emerged in the use of inhaled NO
in sepsis as a means to attenuate or reverse some of the
pulmonary pathophysiology associated with sepsis. Dr
Claes Frostell (Karolinska Institute, Stockholm, Sweden)
overviewed this area of research. He concluded that
inhaled NO in sepsis appears to improve pulmonary
haemodynamics acutely and reduces neutrophil infiltration
into the lung, but the long-term benefit in terms of patient
survival rate is unclear. Dr Lars Bjertnaes (Department of
Anaesthesiology, University of Tromso, Norway) and his
group presented data from studies with DS-1, a novel
selective pulmonary vasodilator compound, in endotox-
aemic sheep. The compound attenuated pulmonary hyper-
tension without affecting systemic haemodynamic
parameters, and improved pulmonary extravasation and
oxygen extraction. It was speculated that compounds such
as this may eventually become a viable future alternative to
NO gas inhalation in the clinical setting.
The proinflammatory side of sepsis and septic shock
received less attention at the meeting than in previous
meetings, probably due to the disappointments with clin-
ical trials with anticytokine therapies. Dr Helge Opdahl
(Ulleval Hospital, Oslo, Norway) overviewed the evi-
dence that shows that traditionally administered cate-
cholamines, in addition to acting as pressor agents, exert
effects as immuno/inflammatory modulators. A clear neg-
ative correlation between lipopolysaccharide-stimulated
IL-1 production and plasma dopamine levels was noted
in ex vivo whole-blood assays, supporting the anti-inflam-
matory effects of catecholamines, presumably acting via
cAMP-mediated processes in the mononuclear cells of
septic patients. Dr Szabo presented a state-of-the-art
lecture on the activation and possible role of nuclear
factor-kB activation in sepsis. This factor appears to be a
clinical target, because it is clearly elevated in septicCritical Care    August 2001 Vol 5 No 4 Investigational Drugs database
patients, its levels correlate with the severity of the
disease, and inhibition of its activation exerts multiple
protective effects in experimental models. The commonly
used antioxidant compounds exert nonspecific effects,
however, and no preclinical or clinical trials are available
with more specific approaches, such as selective
inhibitors of I-kB kinases. Dr Vladimir Kuklin (State Uni-
versity of Arhangelsk, Russia) presented a 100-patient
study of severe sepsis, and demonstrated that plasma-
pheresis reduces mortality rate from 56 to 34%
(P < 0.05), presumably by removing toxic metabolic
byproducts or proinflammatory mediators in sepsis.
Apart from transient episodes of hypotension, no side
effects of the treatment were noted.
Pain management
Pain management was another area of intense interest. Dr
Tor Tennessen (Department of Anesthesiology, The
National Hospital, Norway) overviewed the new options
for treatment and concluded that the following are worthy
of pursuing: diminished use of strong opioids; effective
doses of paracetamol and nonsteroidal anti-inflammatory
drugs; glucocorticoids; and combinations of various nono-
pioid analgesics. Dr Reijo Korpela (Hospital for Children
and Adolescents, Helsinki, Finland) concluded that the
combined use of paracetamol and one nonsteroidal anti-
inflammatory drug would be the optimal method for reliev-
ing postoperative pain in children.
Neurotrauma: novel markers and sedation
supplements
Dr Bertil Romner (Department of Neurosurgery, University
of Tromso) presented novel data for potential serum
markers of traumatic brain injury: neurone-specific
enolase, gliar fibrillary acidic protein and S-199b protein.
Promising clinical data were presented, especially for the
latter protein.
In an intervention study conducted in 427 patients with
head trauma, Dr N Juul (Aarhus University Hospital,
Denmark) failed to report any added benefit with NMBA
(the neuromuscular blocking agent Selfotel) as a supple-
ment to sedation, and questioned the use of such agents
as routine part of the sedation strategy.
Antioxidants in recovery from bypass surgery
In a small-scale study that involved cardiopulmonary
bypass patients, a mixture of antioxidants (Vitamins E and
C, allopurinol and acetylcysteine) improved endothelial
function after surgery. However, further work is needed to
determine whether this change will transfer into improved
clinical outcomes.
Conclusion
The meeting continues to be the leading anaesthesiology
and intensive care conference in the region.